[HTML][HTML] Cholinesterase inhibitors as Alzheimer's therapeutics
K Sharma - Molecular medicine reports, 2019 - spandidos-publications.com
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …
syndrome of the central nervous system that causes a decline in cognitive function and …
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review
Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the
oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine …
oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine …
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder which results
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …
New 3d multifunctional metal chelates of sulfonamide: spectral, vibrational, molecular modeling, DFT, medicinal and in silico studies
We are reporting a new synthetic design of sulfonamide entangled Schiff base ligands as H
2 L 1 and H 2 L 2 from 4-amino-N-(3-methyl-1, 2-oxazol-5-yl) benzene-1-sulfonamide and …
2 L 1 and H 2 L 2 from 4-amino-N-(3-methyl-1, 2-oxazol-5-yl) benzene-1-sulfonamide and …
Probing fluorinated motifs onto dual AChE-MAO B inhibitors: rational design, synthesis, biological evaluation, and early-ADME studies
M Rullo, M Cipolloni, M Catto, C Colliva… - Journal of Medicinal …, 2022 - ACS Publications
Bioisosteric H/F or CH2OH/CF2H replacement was introduced in coumarin derivatives
previously characterized as dual AChE-MAO B inhibitors to probe the effects on both …
previously characterized as dual AChE-MAO B inhibitors to probe the effects on both …
Chromone, a privileged scaffold in drug discovery: Developments in the synthesis and bioactivity
AT Benny, SD Arikkatt, CG Vazhappilly… - Mini Reviews in …, 2022 - ingentaconnect.com
Chromones are the class of secondary metabolites that broadly occur in the plant kingdom
in a noticeable quantity. This rigid bicyclic system has been categorized “as privileged …
in a noticeable quantity. This rigid bicyclic system has been categorized “as privileged …
Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics
Neurodegenerative disorders, ie, Alzheimer's or Parkinson's disease, involve progressive
degeneration of the central nervous system, resulting in memory loss and cognitive …
degeneration of the central nervous system, resulting in memory loss and cognitive …
[HTML][HTML] Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to
dementia and patient death. AD is characterized by intracellular neurofibrillary tangles …
dementia and patient death. AD is characterized by intracellular neurofibrillary tangles …
Challenges and opportunities in central nervous system drug discovery
The development of new drugs for disorders of the central nervous system (CNS) presents
unique challenges when compared with other disease areas. These include an incomplete …
unique challenges when compared with other disease areas. These include an incomplete …
(±)-BIGI-3h: Pentatarget-directed ligand combining cholinesterase, monoamine oxidase, and glycogen synthase kinase 3β inhibition with calcium channel antagonism …
L Ismaili, J Monnin, A Etievant, RL Arribas… - ACS Chemical …, 2021 - ACS Publications
Multitarget-directed ligands (MTDLs) are considered a promising therapeutic strategy to
address the multifactorial nature of Alzheimer's disease (AD). Novel MTDLs have been …
address the multifactorial nature of Alzheimer's disease (AD). Novel MTDLs have been …